# A Study of NST-628 in Recurrent Grade 4 Glioma

Source: https://onco.cc/trials/nct07784985/  
OnCo record `nct07784985` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NST-628 run by Nader Sanai, not yet recruiting.

## Summary

A Study of NST-628 in Recurrent Grade 4 Glioma is a phase 1 interventional study registered as NCT07784985 by Nader Sanai, with 12 participants planned, started 2026-10. Conditions recorded: Glioma, Recurrent High Grade and Grade 4 Malignant Glioma. Interventions recorded: NST-628.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07784985
- Phase: 1
- Setting: A Phase 0/1 Study of NST-628 in Participants With Recurrent Grade 4 Glioma Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration With Pharmacodynamic (PD) Triggered Expansion Cohort
- Sponsor: Nader Sanai
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07784985: https://clinicaltrials.gov/study/NCT07784985

## Connected records

- cancers: [Brain and spinal cord tumours (all types)](https://onco.cc/cancers/brain-tumours/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [NST-628](https://onco.cc/drugs/nst-628/)
- companies: [Nested Therapeutics](https://onco.cc/companies/nested-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07784985.json